Though combination treatment of GDTc, zoledronate and IL-2 in their xenograft model eradicated bioluminescence signals and greatly improved survival, the in vivo model pathology in that case did not resemble CML. Here, IL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.